(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Building an Individual Brand: Illustrations from Forces to be reckoned with - 2The most effective method to Go Down Abundance through Ages with Disc Rates
- 3Taylor Frankie Paul's domestic violence case is fueling discussions about DARVO. Experts say terms like this shouldn't be used lightly.
- 4Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- 510 Moves toward Start Your Own Effective Business
- Top notch Remote Earphones for Audiophiles
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Strength training is crucial after menopause. How to make the most of your workouts
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Vote in favor of the Top Vegetable for Senior
